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ABSTRACT
Breast cancer is the most common malignancy that develops in women worldwide, its incidence continues to rise and it
is responsible for the highest death rates. Breast cancer can be classified as sporadic or familial – the strongest risk
factor today is a family history. Germline mutations in high-penetrance breast cancer susceptibility genes BRCA1 and
BRCA2 have been strongly implicated in the genetic predisposition of approximately 20% of familial breast cancers.
Although BRCA1 and BRCA2 do not account for all familial breast cancers, there are currently no other genes that
have been identified which segregate with familial breast cancer as strongly. Despite large-scale attempts to identify
genetic risk factors associated with breast cancer, the variants identified through genome-wide association studies
(GWAS), only confer a modest increase in risk of breast cancer and at present lack clinical utility. This review will
discuss the known genetic risk factors for developing breast cancer and how far the field has progressed since the
identification of BRCA1.
INTRODUCTION
Breast cancer is the most common malignancy that
develops in women worldwide, its incidence continues to
rise and it is responsible for the highest death rates [1].
Breast cancer is a disease with complex aetiology with
multiple predisposing factors. There is a substantial body
of experimental, clinical and epidemiological evidence
indicating that hormones play a major role in the
development of breast cancer and this has been extensively
reviewed in the literature [2-6]. Firstly, breast cancer in men
is rare, suggesting an influence of the female sex steroids
[7]. Secondly, in studies conducted as early as 1896, it was
reported that removal of the ovaries caused the regression
of breast cancer, and subsequent studies, many years later,
reported that the estrogen antagonist, Tamoxifen, had
proven efficacy in the treatment of advanced breast cancer
and in the reduction of breast cancer risk when used in an
adjuvant setting [3, 8, 9]. Thirdly, it has been repeatedly
demonstrated that estrogen and progesterone treatment in
animal models, including rodents and monkeys, can
promote mammary carcinogenesis and this is critically
dependent on functional estrogen and progesterone
receptors (ER and PR) [3-5]. Finally, there have been
numerous epidemiological studies which have reported
increases in breast cancer risk in women with increased
exposure to endogenous and exogenous hormones [10,
11]. Endogenous and exogenous hormones can promote
tumour formation by driving cell proliferation, subsequently
increasing the number of cell divisions as well as the
opportunity for random genetic errors [2]. Alternatively,
estrogen metabolites may directly generate DNA damage,
thus leading to genomic instability [12, 13]. However, there
is also strong evidence for a genetic component to breast
cancer, the strongest risk factor today is a family history.
The genetic basis for the inherited predisposition to breast
cancer has been ardently investigated in the past two
decades and has resulted in the discovery of several high-
to low-penetrance breast cancer susceptibility genes
through genome-wide linkage studies and mutational
screening of candidate genes in large breast cancer case
series. This review will discuss the known genetic risk
factors for developing breast cancer with a particular focus
on BRCA1.
HIGHLY PENETRANT BREAST CANCER
SUSCEPTIBILITY GENES
BRCA1/2
Hereditary breast cancer accounts for a small but significant
proportion (12.9%) of all breast cancers [14]. Analysis of
pedigrees from high-risk breast/ovarian cancer families led
to the identification and cloning of the first breast cancer
susceptibility gene (BRCA1) [15, 16] spanning
approximately 100kb of genomic DNA and consisting of 24
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exons (although exons 1 and 4 are non-coding), that encode
a large multi-domain protein of 1863aa [16]. The role of this
protein in genetic susceptibility to breast and ovarian
cancer was confirmed when germline mutations in BRCA1
were identified in individuals with a family history of breast
and/or ovarian cancer [16-18]. In addition to an elevated
risk of breast and ovarian cancer, BRCA1 mutation carriers
were also found to have an increased risk of colon,
pancreatic, endometrial, cervical and prostate cancer [19-
23]. However, the risk of cancer at these sites is relatively
small when compared to the risk of cancer in the breast or
ovary. Direct evidence that BRCA1 acted as a tumour
suppressor in human breast and ovarian cancer cells came
from in vitro studies where its over-expression retarded
cell growth and its inhibition accelerated cell growth, while
mutated forms of the protein had no effect [24, 25]. A second
breast cancer susceptibility gene, BRCA2 was
subsequently identified in 1994 [26].
The histopathology of breast cancers diagnosed in
BRCA1 mutation carriers differ substantially from those
that occur in sporadic disease. Breast cancers that develop
in BRCA1 mutation carriers are diagnosed at younger age,
are of higher grade, often exhibit higher mitotic counts and
have a greater proportion of tumour with continuous
pushing margin [27-36]. Breast tumours in BRCA1 mutation
carriers are more likely to be negative for ER, PR and AR
when compared to sporadic breast cancers [34, 37-44]. They
contain less tubule formation, more nuclear polymorphism
and more lymphocytic infiltrate compared with their
sporadic counterparts [29-31]. In addition, BRCA1 mutation
carriers are more likely to develop contralateral breast cancer
[27, 39]. Premalignant lesions associated with increased
malignancy, such as ductal carcinoma in situ (DCIS),
atypical ductal hyperplasia (ADH), and atypical lobular
carcinoma (ALH), may be more prevalent in the normal
breast tissue from BRCA1 mutation carriers compared to
the breast of patients without a known genetic
predisposition to the disease [45-48]. Thus, women with
an inherited predisposition to breast cancer due to a BRCA1
mutation often present clinically with breast tumours
containing features associated with a highly proliferative
phenotype and with a worse prognosis.
To date, more than 1600 distinct pathogenic mutations,
polymorphisms and variants in the BRCA1 gene have been
identified. In addition, over 1800 distinct pathogenic
mutations have been identified in BRCA2 [49]. The
mutations are scattered throughout the entire coding region
of the genes and show no clustering or “hot spots”. The
frequency of these mutations varies widely among different
populations and is influenced by founder effects. For
example, in the Ashkenazi Jewish community four mutations
are thought to account for the majority of inherited breast
and/or ovarian cancer: 185delAG, 188del11 and 5382insC in
the BRCA1 gene and 6174delT in the BRCA2 gene [50]. In
original analyses by the Breast Cancer Linkage Consortium
(BCLC), BRCA1 mutations were shown to occur in > 90%
of families that contained at least four breast and/or ovarian
cancers; and were estimated to occur in 45% of sporadic
cases [51, 52]. However, since the cloning of this gene [16],
the prevalence estimates for BRCA1 have been much less
than those estimated by initial linkage studies.
In hereditary breast cancer, mutations in BRCA1 have
been shown to occur in the large proportion of cases (~30-
80%) in families with both breast and ovarian cancer,
whereas BRCA2 mutations account for a smaller proportion
(~15-20%) [52-58]. In families containing breast cancer only,
BRCA1 mutations occur in around 7% of cases where there
is more than one first degree relative and in 28% of cases
where there are four or more affected individuals within a
family [53, 59]. BRCA1 mutations are more prevalent in
ovarian cancer only families (compared to breast cancer
only families) and are detected in 31-38% of cases [60-62].
The prevalence of BRCA1 mutations in population-based
studies is considerably lower than those estimated for large
multiple-case families. Perhaps the most reliable estimate
to date comes from a study conducted by Antoniou and
colleagues, where population-based cohorts from 22
previous studies in 13 different countries were analysed.
From 8139 index cases presenting with breast or ovarian
cancer, 3.5% were found to carry a mutation in BRCA1 and
2.7% carried a mutation in BRCA2 [63]. Moreover, breast
cancer incidences were shown to increase with age, up to
age 45-49 years in BRCA1-mutation carriers, but reached a
plateau thereafter, whereas breast cancer incidence BRCA2-
mutation carriers increased gradually with age [23, 60, 64].
Although BRCA1 and 2 mutations are found in a high
proportion of familial breast/ovarian cancer patients,
defining the penetrance (the risk that a given mutation will
lead to cancer) of BRCA1 mutations remains a challenging
task. Early studies of large multiple-case families suggested
that the lifetime risk of disease may be as high as 85% in
BRCA1 or BRCA2 mutation carriers [19, 51-53]. However,
more recent analyses have shown significantly lower risks
than those initially estimated, 65% for the risk of breast
cancer development and 39% for the risk of ovarian cancer
development up to 70 years of age for BRCA1 mutation
carriers [23, 60, 64]. The risk estimates for developing breast
or ovarian cancer for BRCA2 mutation carriers are lower
than that of BRCA1 mutation carriers at 45% (breast) and
11% (ovarian) respectively [23, 60, 64]. Nevertheless,
regardless of the precise penetrance estimate, BRCA1 and
2 are highly penetrant (albeit not completely) breast cancer
susceptibility genes whose mutation significantly increases
the risk of developing breast cancer.
DOES BRCA1 MUTATION POSITION ALTER DISEASE
PHENOTYPE?
A critical question in mutation screening of BRCA1 is
whether the position of the mutation correlates with the
cancer phenotype (i.e. breast or ovarian cancer). Knowing
the biological consequence of a particular mutation could
provide valuable information to patients seeking
counselling on which type of preventative and management
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measures to undertake, if a mutation is found. The first
formal evidence linking risk to mutation position came from
Gayther et al. (1995) who found that for 22 different
mutations in 32 families, the ratio of breast to ovarian cancer
was significantly lower after a “change point”. This change
point was codon 1435 in exon 13, where a BRCA1 mutation
5’ of this codon confered a significantly higher risk of
developing ovarian cancer [65]. This has been confirmed
by a study conducted in the UK [66], however, other studies
have failed to confirm a relationship between mutation
position and cancer phenotype [67, 68].
In a population-based study of women with BRCA1-
related ovarian cancer, the risk of breast cancer in first
degree relatives was found to increase proportionally as
the mutation position approached the carboxyl terminus of
the gene [69]. In contrast to previous reports, a study
conducted by the Breast Cancer Linage Consortium of 356
BRCA1-related families found that mutations in the central
portion of the gene (nucleotides 2401-4190) had a
significantly higher ovarian: breast cancer ratio when
compared to mutations between nucleotides 1-2400 or
nucleotides 4191-end [70]. This was supported by an
Australian study which, although subjects with ovarian
cancer were not included, found that mutations within the
central portion of the gene (2356-4592) were associated
with a decreased risk of breast cancer, compared to
mutations at the N- and C-terminus [64]. Furthermore, the
same genotype-phenotype relationship was also observed
in a meta-analysis of 22 previous studies, although
statistical significance was not achieved [63].
Although it is possible that the position of the mutation
within BRCA1 will affect the prevalence of breast or ovarian
cancer, there is no solid evidence as yet, to suggest that
this is the case. The available research is limited and has
produced conflicting results as to which mutated regions
present greater risk for breast or ovarian cancer.
OTHER HIGH PENETRANCE BREAST CANCER
SUSCEPTIBILITY GENES
High penetrance breast cancer susceptibility genes, other
than BRCA1/2, have been identified as a result of their
association with other inherited cancer syndromes and
include TP53, PTEN and STK11.
The p53 tumour suppressor protein is essential for the
response to DNA damage and is classed as a “guardian of
the genome” [71, 72]. The involvement of the p53 protein,
encoded by TP53, in multiple cellular pathways involved
in tumour suppression has long been established, and
somatic mutations in the gene are frequently observed in
many types of solid tumours [73]. Germline mutations in
TP53 cause Li-Fraumeni syndrome, an inherited disorder
that greatly increases susceptibility to breast and other
cancers. Although if present they are highly penetrant,
conferring up to a 10 fold increase in the risk of developing
breast cancer, these mutations are very rare and account
for a much lower familial risk than BRCA1 and BRCA2 [74].
Moreover, they are uncommon in non-Li-Fraumeni breast
cancer families [74, 75].
Germline mutations in PTEN and STK11 are known to
lead to Cowden and Peutz-Jeghers syndrome respectively
[76, 77]. Individuals with Cowden syndrome have an
estimated 30-50% risk of developing breast cancer by the
age of 70 years [76], while the risk of developing breast
cancer is approximately 45% in individuals with Peutz-
Jeghers syndrome [78, 79]. However, PTEN and STK11
mutations are rare in high risk breast/ovarian cancer
individuals that do not carry BRCA1/2 mutations [80, 81].
Interestingly, gross aberrations in PTEN were found in
BRCA1 heterozygous mutation carriers and loss of PTEN
expression was associated with basal-like sporadic breast
cancer cases, indicating that its loss may be tightly linked
with deficiencies in the double-strand break DNA repair
pathway [82].
Together, mutations in BRCA1/2, TP53, PTEN and
STK11, although highly penetrant, only account for around
20-25% of the familial risk of breast cancer. Moreover,
mutations in TP53, PTEN and STK11 are rare in patients
who do not have the cancer syndromes associated with
these genes and they are unlikely to contribute to a
substantial fraction of breast cancer susceptibility in high-
risk breast cancer families who do not harbour inactivating
mutations in the BRCA1/2 tumour suppressor genes.
VARIANTS IN BREAST CANCER SUSCEPTIBILITY
GENES WITH INTERMEDIATE PENETRANCE
Four intermediate-penetrance breast cancer susceptibility
genes, CHEK2, ATM, PALB2, and BRIP1, were identified
through direct re-sequencing of candidate genes in familial
association studies. Disease-causing mutations in these
genes are predominantly ones that cause premature protein
truncation, but are rare and confer a relative risk of breast
cancer of 2- to 4-fold. All four genes are involved in the
BRCA1 DNA repair pathway.
ATM AND CHEK2
BRCA1 is a target for phosphorylation by several
checkpoint kinases in response to DNA damage. The
kinases that participate in this signalling cascade upstream
of BRCA1 include ATM and the checkpoint protein CHEK2.
ATM is a protein kinase that is structurally related to the
phosphoinositide-3 kinase (PI3K)-related kinase family and
is a central component of the DNA damage response [83,
84]. CHEK2 is activated by ATM and the phosphorylation
of BRCA1 by CHEK2 has been shown to govern which
pathway DNA damage will be repaired by: phosphorylation
of BRCA1 at Ser-988 promotes the repair of damaged DNA
by homologous recombination (error-free), while
suppressing repair by non-homologous recombination
(error prone) [85]. It was demonstrated by Renwick and
colleagues that monoallelic ATM mutations were present
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in 2.04% of familial breast cancer cases and were associated
with a 2.37 fold increased breast cancer risk [86]. The
CHEK2*1100delC was found to have a frequency of 1.1%
in healthy individuals and 5.1% in individuals with breast
cancer from 718 BRCA1 or BRCA2 mutation negative
families [87]. In the largest study to date, involving over
26,000 cases and 27,000 controls, heterozygosity for the
CHEK2*1100delC was associated with a 3-5 fold increase
in the risk of developing breast cancer. Furthermore, in
familial breast cancer cases the CHEK2*1100delC was
associated with a 37% lifetime risk of breast cancer, which
was almost as high as the lifetime risks conferred by
mutations in BRCA1 or 2 in this study [88].
BRIP1 AND PALB2
BRIP1 and PALB2 encode for proteins that co-localize with
BRCA1 and BRCA2 to mediate the repair of DNA double-
strand breaks [89-92]. Truncating mutations arising in these
genes are rare, exhibited in approximately 0.1% of the United
Kingdom breast cancer cohort, and confer an approximately
two-fold increase in the risk of breast cancer compared to
population risks [89, 90]. Founder mutations have been
observed in French-Canadian, Finnish and Polish
populations, allowing for the identification of a gene-
disease association [93-95]. However, mutations in BRIP1
and PALB2 show incomplete segregation with disease in
relatives of probands who have breast cancer [89, 96],
making it difficult to use this information in predictive
screening to estimate individual breast cancer risk. There
is no evidence to date that monoallelic mutations in BRIP1
and PALB2 confer a phenotype beyond predisposition to
breast cancer, although biallelic mutations in these genes
are implicated in Fanconi anemia [97].
Inactivating mutations in the intermediate penetrance
genes ATM, CHEK2, BRIP1 and PALB2 are rare, with fewer
than 1% of the population being heterozygote for these
variants. Collectively, mutations in these genes account
for approximately 2.3% of the familial breast cancer risk
[89].
THE IDENTIFICATION OF NEW LOW RISK
VARIANTS
GENETIC MODIFIERS OF RISK IN THE GENERAL
POPULATION
Since the identification of BRCA1 twenty years ago [15,
16], numerous studies have used candidate gene
approaches to identify other breast cancer susceptibility
genes (BRCAx) whose mutations may lead to an increased
risk of breast cancer, with limited success - BRCAx still
remains elusive. Mutations in the high and moderate
penetrance breast cancer susceptibility genes described
above account for approximately 25% of breast cancers;
are rarely found in sporadic cases and thus, much of the
genetic component of breast cancer risk remains to be
characterised. The majority of breast cancers do not arise
through typical patterns of familial inheritance, they occur
sporadically. Sporadic breast cancers differ markedly from
familial breast cancers; with respect to their age of onset
(post-menopause versus pre-menopause), their phenotype
(receptor positive versus receptor negative in BRCA1
mutation carriers) and their clinical behaviour (familial breast
cancers tend to be more aggressive). Thus, candidate gene
approaches in large familial pedigree studies are likely to
miss common genetic variation that confers a risk of breast
cancer in the majority of the population. Genome-wide
association studies (GWAS) in very large study
populations of breast cancer cases and unaffected controls
have gained momentum in recent years, enabling an
unbiased investigation of genetic variation across the
whole genome, as opposed to examination of selected
variants in a few key genes, in an effort to discover new
breast cancer susceptibility loci. To date, 13 breast cancer
susceptibility loci have been discovered by these
approaches (Table 1). None of the identified variants are in
the coding regions of genes, although some of the regions
contain or are nearby known genes (e.g. FGFR2, MAP3K1,
RAD51L) and five of the variants are located in non-genic
regions (1p11.2, 2q35, 3p24, 5p12, 8q24) [98-104]. The
Table 1. Classes and key features of known breast cancer susceptibility genes [98-104]
Class of Breast Cancer Key Features
Susceptibility Genes Genes/Alleles Frequency Risk of breast cancer Risk variants
High-penetrance BRCA1, BRCA2, TP53 Rare (population 10 to 20 fold relative Multiple, different
breast cancer carrier frequency risk mutations that
susceptibility genes < 0.1%) predominantly cause
protein truncation
Intermediate- ATM, CHEK2, BRIP1, PALB2 Rare (population 2 to 4 fold relative Multiple, different
penetrance breast carrier frequency risk [150-153] mutations that
cancer susceptibility < 0.6%) predominantly cause
genes protein truncation
Low-penetrance rs2981582 (FGFR2, 10q), rs3803662 (TOX3, 16q), Common up to ~1.25 fold Single nucleotide
breast cancer rs889312 (MAP3K1, 5q), rs3817198 (LSP1, 11p), (population frequency (heterozygous) or polymorphisms (SNPs)
susceptibility alleles rs1045485 (CASP8, 2q), rs13281615 (8q), 5-50%) 1.65 fold that are causal or in
rs13387042 (2q), rs10941679 (5p), rs2046210 (6q), (homozygous) linkage disequilibrium
rs4973768 (SLC4A7, 3p), rs6504950 (COX11, 17q), relative risk with the causal variant
rs8009944 (RAD51L1, 14q), rs11249433 (1p)
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individual variants confer only a modest increase in the
risk of breast cancer, of up to approximately 1.65 fold.
Importantly, candidate gene approaches and the recent
GWA studies have found no evidence that common
variants in high risk breast cancer susceptibility genes such
as BRCA1/2, TP53, ATM and CHEK2 are associated with
increased breast cancer risk [105, 106]. In fact, few of the
genes in the regions identified by GWAS had previously
been reported to be associated with breast cancer. The
strongest association with breast cancer risk was found
for a SNP located in intron 2 of FGFR2 (rs2981582), where
women carrying two copies of the high risk allele were
observed to have a 1.63 fold increased risk when compared
to women who carried two copies of the low risk allele [98].
The FGF signalling pathway has previously been shown
to induce mammary tumours in mouse models [107] and in
particular, amplification of FGFR2 has been shown to occur
in 5-10% of human breast cancers [108, 109]. Recent studies
by Meyer et al., have demonstrated that homozygotes for
the high risk FGFR2 allele have increased expression of
FGFR2 and functional studies have indicated that this is
due to altered binding affinity of FGFR2 for the transcription
factors Oct-1 and C/EBPb [110]. This was the first study to
determine a biological consequence caused by variants
identified through GWA studies and clearly demonstrates
a mechanism that may lead to increased breast cancer risk
in individuals who are homozygous for the high risk FGFR2
allele. However, a functional consequence for many of the
variants still remains at large and the biological mechanisms
underlying the observed increase in breast cancer risk are
unknown.
It is apparent that each individual variant identified
through GWA studies only accounts for a modest increase
in the risk of developing breast cancer, suggesting that
most of the unexplained breast cancer risk could be
accounted for by a polygenic model, where risk alleles act
multiplicatively [111]. A recent study by Reeves et al. (2010)
comparing 13 risk alleles (Table 1 and ATM: rs1800054) in
10 306 women with breast cancer and 10 393 women without
breast cancer; has investigated the combined effect 7 SNPs
that were most strongly and significantly associated with
breast cancer risk individually [112]. Odds ratios (ORs) were
shown to increase from 0.75 to 1.45 for cases in the bottom
fifth quintile compared to cases in the top fifth quintile,
however, ORs in the top fifth quintile did not differ greatly
from the OR of the individual FGFR2 allele (1.20), which
showed the strongest association with breast cancer risk.
The cumulative risk of developing breast cancer was 8.8%
for cases in the top fifth quintile compared to 4.4% for
cases in the bottom fifth quintile. Thus, although a
polygenic risk model for the variants has been
demonstrated, the cumulative lifetime risk (8.8%) of
developing breast cancer in women in the top fifth quintile
was shown to be similar to that of women with one affected
first-degree relative (9.1%) and far less than that of women
with two affected first-degree relatives (15.4%) [112]. In
addition, it has been demonstrated that 12 of the identified
variants show no interactions with other risk factors for
breast cancer including HRT, age at menopause, age at
menarche, BMI and parity [113]; and variants identified
from GWA studies conducted by Hunter et al., [104] and
Thomas et al. [100] were found to have no association with
breast cancer survival [114]. Thus at this stage, polygenic
risk scores are not a useful tool to inform women of their
risk of developing breast cancer and appear to have limited
utility in breast cancer prognostication.
GENETIC MODIFIERS OF RISK IN BRCA MUTATION
CARRIERS
Given the substantial heterogeneity in penetrance
estimates for BRCA1 mutation carriers between studies of
different populations, in addition to the variation in
penetrance estimates observed between individuals, it is
reasonable to postulate the existence of other factors which
may modulate the risk of cancer in BRCA1 mutation carriers.
In this way, “modifiers” may act in conjunction with the
mutated BRCA1 allele to bring about an earlier diagnosis
in an individual, thus affecting the penetrance of this gene.
Candidate gene approaches have identified several
genetic variants that may alter the risk of breast cancer in
BRCA1 mutation carriers. There are several reports that
allelic variants of the Androgen Receptor (AR) and the
Amplified In Breast Cancer 1 (AIB1) gene, can modify the
risk of breast cancer in BRCA1 mutation carriers [115-117].
However, other studies have found no excess breast cancer
risk in BRCA1 mutation carriers according to their AR allele
or AIB1 polymorphism status [118-122]. TP53 may also
play a role in BRCA1-related tumourigenesis. TP53 has
been found to be mutated in 53-77% of BRCA1-related
breast cancers, but only in 30-35% of sporadic breast
tumours [123-127]. Likewise, TP53 mutations are found in
50-83% of ovarian cancers linked to BRCA1 compared to
30-49% of sporadic ovarian tumours [128-131]. Thus, the
high rate of TP53 mutations found in cancers of BRCA1
mutation carriers indicates that inactivation of p53 function
may act as a modifier of cancer risk in these women.
However, subsequent studies have found no association
between polymorphisms in TP53 (Arg72Pro) or MDM
(309G > T) (either singly or in combination) and breast
cancer risk in BRCA1 or BRCA2 mutation carriers,
suggesting that the inactivation of TP53 and its signalling
pathway may occur as a result of tumour progression rather
than being a risk modifier [132]. The RAD51 135G > C
polymorphism has been shown to increase breast cancer
risk in BRCA2 mutation carriers by approximately 3 fold,
but does not increase breast cancer risk in BRCA1 mutation
carriers or the general population [133, 134]. Instead, the
RAD51 135G > C polymorphism may protect against the
risk of breast cancer in BRCA1 mutation carriers [135]. There
is also evidence that the 677C > T polymorphism in
Methylenetetrahydrofolate reductase (MTHFR) and the
C to T transition in the 3’ untranslated region of the
Prohibitin (PHB) may increase breast cancer risk in BRCA1
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mutation carriers [136, 137]. Allele variants of the Insulin-
like Growth Factor-1 (IGF1) and the Progesterone
Receptor (PR) are known to alter hormonal sensitivity and
have been shown to modify the risk of breast and ovarian
cancer respectively, in BRCA1 mutation carriers [138, 139].
Polymorphisms in the Harvey Rat Sarcoma 1 (HRAS1)
proto-oncogene as well as common variants of the BRCA1
wild-type allele itself have been shown to increase the risk
of ovarian cancers in BRCA1 mutation carriers [140, 141].
Other groups have reported low expression of the pro-
apoptotic protein B-cell Lymphoma Protein 2 (Bcl-2) and
amplification of the Myelocytomatosis (MYC) oncogene,
in BRCA1-associated breast tumours compared to sporadic
cases [142, 143], but whether these genes act as risk
modifiers in BRCA-related tumourigenesis is unknown.
Numerous other candidate genes have been
investigated as modifiers of BRCA1/2 penetrance, however,
they have been met with limited success. Given the lack of
targets found to positively correlate with breast cancer
risk by candidate gene approaches in BRCA1/2 mutation
carriers, GWAS studies are now being applied to BRCA1/
2 mutation carriers. Initial studies have focussed on
determining whether variants that increase breast cancer
risk in population based-studies confer a similar risk of
breast cancer development in BRCA1/2 mutation carriers.
To this end, five of the variants identified by GWAS (Table
1) have been genotyped in women who are BRCA1 and 2
mutation carriers. While variants in FGFR2, TNCR9, LSP1,
MAP3K1 and the 2q35 region were associated with breast
cancer risk in BRCA2 mutation carriers, only the TNCR9
variant and the 2q35 region was associated with breast
cancer risk in BRCA1 mutation carriers [144, 145]. More
recently, GWA studies have been carried out in BRCA1/2
mutation carriers to identify new modifiers of disease risk
in these individuals. Interestingly, FGFR2 was the only
locus to reach GWAS statistical significance and showed
a similar magnitude of risk (approximately 1.3 fold increased
risk) as reported for breast cancer risk in population-based
studies [146]. Thus, variants that modify breast cancer risk
in the general population also appear to modify breast
cancer risk in BRCA2 mutation carriers. However, this does
not appear to be the case in BRCA1 mutation carriers where
one locus (19p13) containing 5 variants has been reported
to be associated with breast cancer risk in these individuals
and a similar association was also reported for ER-negative
and triple negative cases [147]. These results seem to reflect
the distinct biology of BRCA1-related breast cancers, which
are predominantly hormone receptor negative, compared
to BRCA2-related and sporadic breast cancers, and further
highlights the genetically divergent pathways that lead to
tumourigenesis in these women.
SUMMARY AND CONCLUSIONS
Following the identification of BRCA1 and BRCA2 as high
penetrance breast cancer susceptibility genes, significant
effort has been aimed at identifying further susceptibility
genes that may account for the missing heritability to breast
cancer. The advances made have been small and the elusive
BRCAx has still not been found. This has led to the
conclusion that there are in fact no other high penetrance
breast cancer susceptibility genes and that the remainder
of the genetic risk to breast cancer can be accounted for by
a polygenic model, where many variants of low penetrance
act multiplicatively to increase the relative risk of
developing breast cancer. In the last 3 years, with
considerable advances in technology, a multitude of data
has been generated by GWAS leading to the identification
of 13 new low penetrance variants that individually account
for a modest increase in breast cancer risk. However, the
results have been somewhat disappointing, when combined
these variants still only lead to a small increase in breast
cancer risk and the information generated thus far, will not
be informative in a clinical setting in determining an
individuals’ risk of developing breast cancer and therefore,
will not be useful in preventative strategies.
How far have we come from BRCA1 in predicting breast
cancer risk? To date, most of the GWAS on breast cancer
have been carried out in populations unselected for ER
status, grade, age, ethnicity, etc. But breast cancer is an
extremely heterogeneous disease where gene-environment
interactions, especially those influencing estrogen
exposure, play a major role in determining disease onset
and expression and this has been repeatedly demonstrated.
In this regard, it has been shown that the relative risks for
each of the 13 low penetrance variants are significantly
influenced by ER status (FGRR2, TNCR9), grade (FGRR2,
TNCR9), bilateral disease (2q35) and lobular versus ductal
carcinoma (2q35) [112]. Genetically, sporadic breast cancer
can be subdivided into 5 distinct sub-groups and hormone
receptor status plays a major role in discriminating these
sub-groups [148]. BRCA1-related tumours consistently
group with sporadic tumours that are negative for ER, PR
and HER2, “triple negative” [148]. The most recent GWAS
on BRCA1 carriers highlights the genetic heterogeneity of
breast cancer, where only one locus was shown to influence
breast cancer risk and this locus had not previously been
associated with sporadic disease. This locus was associated
with the risk of developing ER-negative breast cancer and
triple-negative breast cancer, but not ER-positive breast
cancer [147]. Other studies have also shown significantly
stronger associations of many of the 13 identified variants
with ER-positive disease compared to ER-negative disease
and this is especially true of the polygenic model [112].
The most recent GWAS on ER-negative breast cancer
found that there were no significant associations with any
of the variants examined and found no evidence to suggest
that ER-negative breast cancer has a polygenic basis for
disease development, unlike ER-positive breast cancer
[149]. Thus, recent GWAS on breast cancer have reiterated
that importance of viewing breast cancer sub-types as
distinct entities and underpin the genetically diverse
pathways by which these tumour sub-groups develop.
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In conclusion, although the variants identified by
GWAS have little clinical applicability at present, it is likely
that more refined GWA studies of tumour sub-groups with
defined pathological characteristics will shed more light
on risk prediction in the future.
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